New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Ajax Therapeutics is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Vogelbaum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ajax Therapeutics

At Ajax, we are applying uniquely selective approaches to develop novel therapies targeting key cytokine signaling pathways that drive hematologic malignancies. By combining the deep disease, genetics and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery platform from our founding partner, Schrodinger, Inc., we are developing more precisely designed small molecule therapeutics for hematologic malignancies. Ajax has a unique partnership with Schrodinger, Inc. (NASDAQ: SDGR), the industry leader in molecular simulation software for drug discovery, to develop a pipeline of selectively targeted small molecules. Through this ongoing collaboration, Schrodinger and Ajax scientists work as an integrated team to precisely design and optimize compounds with the desired functional activity, selectivity and drug-like properties.

To learn more about Ajax Therapeutics, visit http://www.ajaxtherapeutics.com/

Contact:
Martin Vogelbaum, Chief Executive Officer
646-361-0100
https://www.linkedin.com/in/martin-vogelbaum-9448778/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved